2140879-93-0

Basic information

• Product Name: 8-amino-1,2,3,5,6,7-hexahydro-s-indacene-4-carbonitrile
• CAS NO: 2140879-93-0
• Molecular Weight: 198.268
• Mol File: 2140879-93-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 8-amino-1,2,3,5,6,7-hexahydro-s-indacene-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 8-amino-1,2,3,5,6,7-hexahydro-s-indacene-4-carbonitrile(2140879-93-0)
• EPA Substance Registry System: 8-amino-1,2,3,5,6,7-hexahydro-s-indacene-4-carbonitrile(2140879-93-0)

Safety Data

• Hazardous Substances Data: 2140879-93-0(Hazardous Substances Data)

Upstream product

• 2408331-24-6 8-iodo-1,2,3,5,6,7-hexahydros-indacen-4-amine 
• 557-21-1 zinc(II) cyanide 
• 1995037-57-4 8-bromo-1,2,3,5,6,7-hexahydro-s-indacen-4-amine 
• 14927-64-1 3,5,6,7-tetrahydro-2H-s-indacen-1-one 
• 39105-39-0 3-chloro-1-(2,3-dihydro-1H-inden-5-yl)propan-1-one 
• 496-11-7 INDANE 
• 63089-56-5 1,2,3,5,6,7-hexahydro-s-indacen-4-yl-amine 

Relevant articles and documents

NLRP MODULATORS

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

NOVEL COMPOUNDS

The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.